We are looking forward to EWMA in Amsterdam and will be attending for the whole conference from 3rd to 5th May 2017.
17 March 2015
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.
28 November 2014
Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category. The Engineer’s Product Prize is a prestigious award recognising technologically advanced products that are both novel and are based on significant technical skills and knowledge.
Commenting on the award, the judges stated that “LeucoPatch solves a significant problem among diabetics. It is simple to use and it utilizes the body’s own biology. The product reflects thorough research and has very significant knowledge built into it. Therefore, it wins the Innovation Award.”
27 November 2014
Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life Sciences category. This provided the opportunity to showcase both the company and the LeucoPatch technology in a short film presented to industry and business leaders assembled at the prestigious EY Entrepreneur Of The Year awards event in Copenhagen on 27 November 2014.
22 September 2014
Reapplix announces that the Centers for Medicare and Medicaid Services in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.
10 September 2014
Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer.
13 August 2014
17 July 2014
“Lise Tarnow, TV2 Lorry”:http://www.tv2lorry.dk/arkiv/2014/7/14?video_id=93064
10 July 2014
Clinical sites are continuously being added to the LeucoPatch RCT Recently sites in Lincoln, Dudley and Sheffield have joined us - welcome!
15 October 2013
A study of more than 250 diabetic foot ulcer patients will be initiated in cooperation with principal investigators Dr. Löndahl, Dr. Game, Prof. Jeffcoate and Dr. Tarnow at several multidisciplinary team based clinical sites in UK, Denmark and Sweden.
20 May 2013
Final clinical data from the LeucoPatch diabetic foot ulcer study were presented by Clinical investigator Dr. Bo Jørgensen at the European Wound Management Association meeting held in Copenhagen.